Deutsche Bank estimates that Sandoz, which accounted for 11% of Novartis' group operating profit in 2022, is likely to have a market value of $11-$13 billion, with brokerage Berenberg expecting a ...

Citing Deutsche Bank's estimate, Reuters notes Sandoz's market value of $11-$13 billion, while brokerage firm Berenberg expects a $17-$26 billion valuation range.

The global Biosimilars Market, valued at US$32.75 billion in 2024 stood at US$35.04 billion in 2025 and is projected to ...

Novartis’ generics unit Sandoz will tell investors today that it can add $3 billion in annual sales from the launch of new products, after it spins out of its parent company later this year.

Wyost and Jubbonti are interchangeable with Xgeva/Prolia and are approved for all of the same indications in bone cancer and ...

Sandoz drugs Jubbonti and Wyost are approved for use in all indications covered by the Amgen products, Prolia and Xgeva. But no launch date is planned yet, due to ongoing patent litigation between ...

Sandoz projects the market for biosimilars and generics to double over the next nine years, owing to the aging of the population and significant products—such as Humira and Merck’s Keytruda ...

“Because of [our] credentials of being first to market with many biosimilars and generic products, we were selected by Sandoz to do this transaction in Colombia,” he explained.

Sandoz, whose first day of trading is scheduled for Oct. 4, has previously said its development pipeline has 25 future biosimilars, cheaper versions of off-patent biologic drugs made from modified ...

Sandoz plans to launch at least five additional biologic drugs, its CEO Richard Saynor said, as the generics drugs business of Switzerland's Novartis works to enhance its investor appeal ahead of ...

Sandoz plans to launch at least five additional biologic drugs, ... as the generics drugs business of Switzerland's Novartis works to enhance its investor appeal ahead of its market debut next month.